A 26-year-old transgender man (assigned female at birth) presents to his family physician requesting masculinizing hormone therapy. He has socially transitioned and wants a deeper voice and a more masculine body habitus. He understands the expected changes and the risks, and he has the capacity to consent. He is sexually active with a cisgender male partner and uses condoms inconsistently. He has a cervix and has never had cervical screening. He smokes 1 pack of cigarettes per day, takes no medications, and has no known allergies. There is no history of coronary artery disease, venous thromboembolism, or polycythemia. Examination is unremarkable. Urine hCG is negative. Hemoglobin is 138 g/L (115-155), hematocrit 0.41 (0.36-0.46), and liver enzymes and fasting lipids are normal.
| Heart rate | 70/min |
| Respiratory rate | 14/min |
| Temperature | 36.8 °C |
| O2 saturation | 99%, room air |
| Blood pressure | 118/72 mm Hg |
Question 1 of 3
Which of the following are the most appropriate medication options to start masculinizing hormone therapy in this patient?
Select 2. (0 / 2 selected)
Tip: right-click an answer (or press and hold on a phone) to strike it out. Drag over the question text to highlight it.